Stock Picks

You are not logged in to our page, as a result you are seeing 15 of our top performing stock selections within the last 2 months. To see all the positions including those currently open in our portfolio, please register for a free trial account.
arrow-rightRegister For a Free Trial arrow-rightProducts and Services arrow-rightPortfolio Performance
Show trades in of

Long Position on PBYI @ $57.80 on 5/24/2017 (Rumor)

We recommnded this stock on Monday at $37.80. Shares hit $69.66 the same day. We are recommending it again as  FDA meets to rule on the company's drug.

Bullish Flag on PBYIPuma Biotechnology, Inc. (PBYI) is a biopharmaceutical company.

The firm focuses on the development and commercialization of products to improve cancer care.

Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)).

The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. 

Shares have formed a bullish "flag" following the FDA's meeting on the company's brast cancer drug on Monday. The Committee's briefing document came out on Monday which the committee recommended approving the drug.  The FDA has scheduled a May 24 Advisory Committee meeting for Puma’s neratinib in extended adjuvant treatment of “HER2” early stage breast cancer. In its Q1 earnings report, the company confirmed that “we look forward to presenting” at the May 24 meeting. 

In a post-earnings research note, Citi’s analyst highlights that Puma accelerated plans for final five-year data from the ” #ExteNET ” neratinib trial to Q2 from the second half, as it will be used during the drug’s May 24 #AdComm. The analyst confirmed with Puma that additional data from the “CONTROL” prophylactic trial will also be presented at the meeting.

Out of 100 women treated for two years, two would not get cancer. That's a real but small benefit -- although it might be bigger in a subset of women whose tumors test as hormone-receptor positive. But neratinib came with a downside: diarrhea in 95% of patients. For 40% of patients, the diarrhea was serious. It appears treatment with loperamide, the active treatment in Imodium, can reduce the diarrhea some.

Notably, the analyst says he “noticed” that Puma appears to be actively hiring for commercial operations, with the company’s website now showing 18 job listings for roles within outreach, commercial supply chain, market access, reimbursement, and other areas. Though critics may interpret the news as signaling that Puma doesn’t expect to be acquired, the analyst counters that such an argument “doesn’t work too well tactically,” as the stock should gain at least 100% on what he calls an “expected positive” AdComm. Higher share prices are expected for this stock.

52-Weeks Trading Range: $27.64 - $73.27

Entry Point: $57.80

Stop Loss: $52.00

Target Price: $66.00

Position closed on 5/24/2017 at price of $72.00 with a 24.57% gain in 0 days.

Long Position on PBYI @ $37.80 on 5/22/2017 (Rumor)

Bullish Flag on PBYIPuma Biotechnology, Inc. (PBYI) is a biopharmaceutical company.

The firm focuses on the development and commercialization of products to improve cancer care.

Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)).

The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. 

Shares have formed a bullish "flag" ahead of FDA's meeting on the company's brast cancer drug.  The FDA has scheduled a May 24 Advisory Committee meeting for Puma’s neratinib in extended adjuvant treatment of “HER2” early stage breast cancer. In its Q1 earnings report last night, the company confirmed that “we look forward to presenting” at the May 24 meeting. 

In a post-earnings research note, Citi’s analyst highlights that Puma accelerated plans for final five-year data from the ” #ExteNET ” neratinib trial to Q2 from the second half, as it will be used during the drug’s May 24 #AdComm. The analyst confirmed with Puma that additional data from the “CONTROL” prophylactic trial will also be presented at the meeting.

Notably, the analyst says he “noticed” that Puma appears to be actively hiring for commercial operations, with the company’s website now showing 18 job listings for roles within outreach, commercial supply chain, market access, reimbursement, and other areas. Though critics may interpret the news as signaling that Puma doesn’t expect to be acquired, the analyst counters that such an argument “doesn’t work too well tactically,” as the stock should gain at least 100% on what he calls an “expected positive” AdComm. Higher share prices are expected for this stock.

52-Weeks Trading Range: $27.64 - $73.27

Entry Point: $37.80

Stop Loss: $35.90

Target Price: $41.58

Updates

5/22/2017 10:10:23 AM

PBYI closed at $69.35

Position closed on 5/22/2017 at price of $69.35 with a 83.47% gain in 0 days.

Long Position on IM @ $28.30 on 2/5/2016 (Momentum)

200-day MA on IMIngram Micro Inc. (IM) distributes information technology (IT) products; and provides supply chain and mobile device lifecycle services worldwide.

The company offers printers, scanners, displays, projectors, monitors, panels, mass storage, and tape products; digital signage products; digital cameras and video disc players, game consoles, televisions, audio, small appliances, media management, and home control products; barcode/card printers, AIDC scanners and software, and wireless infrastructure products; Internet protocol video surveillance, security and fire alarm systems, and access control smart cards; processors, motherboards, hard drives, and memory products; and ink and toner supplies, paper, carrying cases, and anti-glare screens.

It also provides rack, tower, and blade servers; desktops; portable personal computers and tablets; and business application, operating system, entertainment, security, storage, and virtualization software products, as well as middleware and developer software tools.

In addition, the company offers switches, hubs, routers, wireless local area networks, wireless wide area networks, network interface cards, cellular data cards, network-attached storage, and storage area networks; VoIP, communications, modems, phone systems, and video/audio conferencing; and firewalls, VPN, intrusion detection, and authentication devices and appliances.

Further, it provides mobile handsets, tablets, navigation devices, aircards, SIM cards, flash memory, and other mobile companion products; supply chain, bid and inventory management, integration, technical support, training, financial and credit, marketing, marketing agency, business intelligence and analytics, e-commerce, managed, cloud, managed print, solution center, professional, and mobility device lifecycle services. The company sells its products to resellers of IT products and services through sales representatives.

The firm reports its quarterly results on February 25th. Ahead of that, shares have move above their 200-day moving average (shown in green). Higher share prices are expected for this stock.

 

52-Weeks Trading Range: $22.54 - $32.09

Entry Point: $28.30

Stop Loss: $26.75

Target Price: $31.15

Updates

2/18/2016 9:34:53 AM

IM closed at $36.10

Position closed on 2/18/2016 at price of $36.10 with a 27.56% gain in 13 days.

Long Position on YY @ $72.50 on 3/3/2014 (Rumor)

This stock was first featured July 2013 at $34.

Bullish Cup & Handle on YYYY Inc. (YY) operates an online social platform in the People’s Republic of China.

It provides YY Client, a personal computer based user software that offers real-time access to user-created online social activities groups.

The company also offers Web-based YY that enables users to conduct real-time interactions on the Web without any downloads or installations; and Mobile YY, a smartphone application.

In addition, it operates Duowan.com, a game media Website that provides information on online games and other resources for users and online game players.

Shares have formed a bullish "cup and handle" and higher share prices are expected for this stock. The Company reports earnings tomorrow, and we are now hearing rumors that the firm will post very strong results. This morning's weakness due to the Ukraine sitatuion, should offer a better entry point for this stock.

52-Week Trading Range: $15.26 - $77.90

Entry Point: $72.50

Stop Loss: $68.88

Target Price: $79.75

Updates

3/4/2014 10:01:11 AM

YY has reached our target price. We are riding it higher as we believe earnings will be strong. YY last traded at $81.00.

3/4/2014 4:24:21 PM

YY Inc. reports Q4 EPS 53c, consensus 46c - Reports Q4 revenue $101.1M, consensus $84.48M. YY Inc. sees FY14 revenue up 98%-102% to RMB 625M-RMB 635M.

We are closing the positon at $94.00 in after hours trading.

Position closed on 3/4/2014 at price of $94.00 with a 29.66% gain in 1 days.

Long Position on VIPS @ $118.00 on 2/28/2014 (Rumor)

This stock was first featured in July 2013 at $39 per share.

Bullish Cup & Handle on VIPSVipshop Holdings Limited (VIPS) operates as an online discount retailer for various brands in the People's Republic of China.

It offers a range of branded discount products, including apparel for women, men, and children; fashion goods; cosmetics; home goods and other lifestyle products; footwear; sportswear and sporting goods; luxury goods; and gifts and miscellaneous products.

The company provides its branded products through its Website vipshop.com, as well as its cellular phone application.  

Vipshop has recently spent nearly $200 million on two acquisitions. On February 14, Vipshop acquired 75% equity interest in Lefeng.com from Ovation Entertainment for $132.5 million. Lefeng owns and operates an online retail website specialized in selling cosmetics and fashion products in China.

This strategic investment provides Vipshop access to a consistent supply of Ovation branded cosmetic products, which are in high demand among Vipshop's growing user base. Vipshop's CEO said in the statement that about 75% of the company's customers are female. Shares have formed a bullish "cup & handle" and higher share prices are expected for this stock.

We are now hearing rumors that when the firm reports on Monday March 3rd, it will have a very strong report. 

52-Week Trading Range: $23.26 - $122.60

Entry Point: $118.00

Stop Loss: $112.10

Target Price: $129.80

Updates

2/28/2014 4:37:02 PM

VIPS, today's Rumor Mill pick has reached our target price. We are holding into earnings but have raised our stop loss to $128! VIPS last traded at $130.58.

3/3/2014 4:13:56 PM

VIPS reports Q4 adjusted EPS 49c, consensus 41c - Reports Q4 revenue $651M, consensus $559.43M. Sees Q1 revenue $640M-$650M, consensus $554.46M. VIPS closed at $127.76. We are closing the position at $143.00 in extended trading.

Position closed on 3/3/2014 at price of $143.00 with a 21.19% gain in 3 days.

Long Position on FRX @ $64.95 on 1/27/2014 (Momentum)

Bullish Flag on FRXForest Laboratories (FRX) develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe.

It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; Teflaro for the treatment of adults with skin and skin structure infections, and community-acquired bacterial pneumonia; Daliresp to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD; and Viibryd for the treatment of adults with major depressive disorder (MDD).

The company has products under new drug application review by Food and Drug Administration comprising Aclidinium for the maintenance treatment of COPD; and Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. It also develops ceftaroline/avibactam combination, which is under Phase III clinical trials for complicated intra-abdominal infections, as well as has completed Phase II clinical trials for complicated urinary tract infections; and Cariprazine that is in Phase III clinical trials for the treatment of acute exacerbation of schizophrenia and acute mania associated with bipolar disorder.

In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; GRT 6005 that is under Phase II clinical trials for nociceptive and neuropathic pain; TTP399, which is under Phase II clinical trials for the treatment of Type II diabetes; and RGH-618 that is under Phase I clinical trials for the treatment of anxiety, depression, and other central nervous system conditions.

Shares have formed a bullish "flag" after the firm reported strong quarterly results and guided higher going forward! Higher share prices are expected for this stock.

 

52-Week Trading Range: $35.22 - $72.40

Entry Point: $64.95

Stop Loss: $61.70

Target Price: $ 71.44   

Updates

2/18/2014 8:43:52 AM

We are taking profits on FRX. Position closed in pre-market trading at $93.15 for a 43% gain.

Position closed on 2/18/2014 at price of $93.15 with a 43.42% gain in 21 days.

Long Position on REGN @ $216.00 on 4/26/2013 (Momentum)

Bullish Flag on REGNRegeneron Pharmaceuticals (REGN) discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally.

The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children.

Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company’s earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. 

Shares have formed a bullish "flag" and higher prices are expected for this stock. 

52-Week Trading Range:   $107.31 - $220.43

Entry Point:  $216.00

Stop Loss:  $205.20

Target Price:   $237.60

Updates

5/1/2013 11:28:48 AM

Shares of Regeneron (REGN) are now higher by 14%, or $29.52, to $244.98 after Allergan (AGN) said its treatment for age-related macular degeneration will not move directly into Phase 3 trials. Regeneron's drug Eylea is a treatment for age-related macular degeneration.

Stock has exceeded our target price but we are keeping the position open due to the news. Our previous target was $237.60. We are now raising our target to $260. 

5/3/2013 9:36:39 AM

REGN has been a great trade for us. We closed the position today at $265. If you elect to stay, adjust your stop loss to $260 to protect your gains.

Position closed on 5/3/2013 at price of $265.00 with a 22.69% gain in 7 days.

Long Position on GNRC @ $25.88 on 10/3/2012 (Momentum)

Bullish Flag on GNRCGenerac Holdings (GNRC) designs, manufactures, and markets a range of generators and other engine powered products for the residential, light commercial, industrial, and construction markets in the United States and Canada.

It offers generators and other products fueled by natural gas, liquid propane, gasoline, diesel, and Bi-Fuel under the Generac and Magnum brands. The company’s product line includes residential power products, commercial and industrial power products, and other products. Its residential power products comprise automatic residential standby generators that range in output from 6kW to 60kW; air-cooled residential standby generators, which range in outputs from 6kW to 20kW; and liquid-cooled generators that range in outputs from 20kW to 60kW.

The residential power product line also includes portable generators consisting of GP series ranging from 1,850W to 17,500W for homeowners; the XG series ranging from 4,000W to 10,000W for the premium homeowner market; the XP series ranging from 4,000W to 8,000W for the professional contractor market; and the iX series ranging from 800W to 2,000W for the recreational market.

The company’s industrial and commercial power products comprise light-commercial standby generators ranging from 22kW to 150kW for grocery stores, convenience stores, restaurants, gas stations, pharmacies, retail banks, and healthcare facilities; single-engine industrial generators, which range in output from 10kW to 600kW; and generator systems ranging from 20kW air-cooled generators to 3mW modular power system for the telecommunications market, as well as aftermarket service parts and RV generators.

The company sells its generators through independent residential and industrial dealers, wholesalers, national accounts, private label arrangements, retailers, catalogs, e-commerce merchants, equipment rental companies and dealers, and construction companies. Shares have formed a bullish "flag" after the firm guided higher. We expect higher prices for the stock.

52-Week Trading Range:  $18.35 - $30.61

Last Trade: $25.88

Stop Loss:  $24.50

Target Price:  $28.45

Updates

10/31/2012 9:46:43 AM

GNRC reported great earnings and guided higher. We are closing the position at $32.88

Position closed on 10/31/2012 at price of $32.88 with a 27.05% gain in 28 days.

Long Position on SEM @ $10.70 on 7/18/2012 (Rumor)

Select Medical Holdings Corporation (SEM) operates specialty hospitals and outpatient rehabilitation clinics in the United States. The company's Specialty Hospitals segment offers long term acute care hospital services and inpatient acute rehabilitative hospital care. This segment provides services for various medical conditions, such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders, and cancer. As of December 31, 2011, it operated 110 long term acute care hospitals and 9 inpatient rehabilitation facilities in 28 states. The Outpatient Rehabilitation segment operates clinics; and provides physical, occupational, and speech rehabilitation services. It offers medical rehabilitation services on a contract basis at nursing homes, hospitals, assisted living and senior care centers, schools, and worksites. This segment also provides specialized programs, such as functional programs for work related injuries, hand therapy, and athletic training services. As of December 31, 2011, it operated 954 outpatient rehabilitation clinics in 32 states and the District of Columbia. We are now hearing rumors of good news for this company. One of the rumors states that this stock will be named by the leading stock advisory service as one of its "top picks." This service is widely followed by mutual funds and institutional money managers. These investors have portfolios that mimic recommendations of this service. Their naming of the stock should lead to additional demand for the shares. Shares are heading higher in a bullish "cup & handle" and are expected to move higher in this formation. The stock has a 52-week trading range of $5.48 - $11.06. Shares last traded at $10.59. Should you decide to take a position, wait for the morning volatility to wear off and use a stop-loss of $10.06 (five percentage points below your purchase price.) Be sure to use a limit order and not a market order. Keep in mind that our price target is 10% higher than your purchase price.

Position closed on 8/8/2012 at price of $14.00 with a 30.84% gain in 21 days.

Long Position on SAH @ $14.20 on 7/12/2012 (Momentum)

Position closed on 7/30/2012 at price of $17.20 with a 21.13% gain in 18 days.

Long Position on PCYC @ $40.50 on 6/15/2012 (Momentum)

Position closed on 7/10/2012 at price of $59.05 with a 45.80% gain in 25 days.

Long Position on LQDT @ $47.99 on 4/11/2012 (Momentum)

Position closed on 5/3/2012 at price of $62.50 with a 30.24% gain in 22 days.

Long Position on SWI @ $37.01 on 4/16/2012 (Momentum)

Position closed on 4/26/2012 at price of $45.80 with a 23.75% gain in 10 days.

Long Position on ASGN @ $13.95 on 2/24/2012 (Momentum)

Position closed on 3/21/2012 at price of $17.70 with a 26.88% gain in 26 days.

Long Position on LULU @ $48.70 on 1/4/2012 (Momentum)

Position closed on 1/17/2012 at price of $61.10 with a 25.46% gain in 13 days.